Crossmark

Successful treatment of relapsed/refractory transformed aggressive B-cell lymphoma with polatuzumab vedotin combined with bendamustine and rituximab followed by non-myeloablative related HLA-haploidentical stem cell transplantation

Crossref DOI link: https://doi.org/10.1007/s00277-023-05366-4

Published Online: 2023-08-10

Published Print: 2023-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kosugi, Shigeki

Kanno, Masatoshi

Inoue, Yasuyuki
License Information

Text and Data Mining valid from 2023-08-10

Version of Record valid from 2023-08-10
More Information

Article History

Received: 26 May 2023

Accepted: 7 July 2023

First Online: 10 August 2023

Declarations

:

: This report was exempt from ethical approval according to the World Medical Association Declaration of Helsinki.

: A written informed consent to publish was obtained from the patient.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below